- Previous Close
10.76 - Open
10.71 - Bid 11.05 x 200
- Ask 11.17 x 300
- Day's Range
10.53 - 11.41 - 52 Week Range
4.60 - 20.90 - Volume
133,636 - Avg. Volume
322,332 - Market Cap (intraday)
487.974M - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-0.49 - Earnings Date Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.33
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
www.ymabs.comRecent News: YMAB
View More
Performance Overview: YMAB
Trailing total returns as of 8/6/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: YMAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: YMAB
View MoreValuation Measures
Market Cap
487.97M
Enterprise Value
413.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.75
Price/Book (mrq)
4.92
Enterprise Value/Revenue
4.89
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-25.64%
Return on Assets (ttm)
-12.02%
Return on Equity (ttm)
-20.93%
Revenue (ttm)
84.5M
Net Income Avi to Common (ttm)
-21.67M
Diluted EPS (ttm)
-0.49
Balance Sheet and Cash Flow
Total Cash (mrq)
75.75M
Total Debt/Equity (mrq)
1.19%
Levered Free Cash Flow (ttm)
-11.46M
Research Analysis: YMAB
View MoreCompany Insights: YMAB
YMAB does not have Company Insights
Research Reports: YMAB
View MoreDaily – Vickers Top Buyers & Sellers for 12/12/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/04/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/30/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 05/18/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.